TechnoGenesys, Inc. is focused on commercialization of a novel epigenetic inhibitor with immune-regulatory activity, (R)-9b that will be targeted to
cAstration-resistant prostate cancer (crpc)
Non-Small Cell Lung Cancers (NSCLC)
Triple negative breast cancer (TNBC)
TechnoGenesys, Inc. is also committed to provide the novel companion diagnostics (CDx) that accurately predict response to treatment with inhibitor (R)-9bMS, in a `personalized medicine’ approach​
